field
immunotherapi
aim
activ
patient
immun
system
host
diseas
immunotherapi
includ
investig
differ
mechan
lead
activ
immun
respons
develop
method
control
respons
desir
manner
combat
diseas
either
singl
strategi
combin
treatment
specif
case
cancer
immunotherapi
specul
vivo
activ
endogen
immun
cell
would
far
sensit
specif
would
exogen
treatment
anticanc
vaccin
thu
design
induc
tumorspecif
effector
cell
tumorspecif
memori
tcell
anticanc
vaccin
hope
induc
regress
establish
tumor
well
prevent
onset
secondari
tumor
metastas
possibl
address
issu
minim
residu
diseas
mrd
case
spars
cancer
cell
evad
irradi
chemotherapi
detect
destroy
immun
system
cell
unlik
temporari
exogen
treatment
present
bodi
time
major
requir
effici
anticanc
vaccin
gener
cytotox
tlymphocyt
ctl
respons
manipul
arm
immun
respons
mainli
helper
cell
critic
robust
long
last
ctl
respons
ctl
respons
gener
depend
antigen
ag
present
mhc
cell
poor
ag
present
activ
demonstr
tumor
cell
highlight
need
profession
apc
gener
desir
ctl
respons
among
sever
type
apc
bodi
dc
suitabl
purpos
ralph
steinman
award
nobel
prize
discoveri
dc
dc
famili
profession
apc
power
apc
equip
special
machineri
enabl
regul
initi
primari
immun
respons
origin
deriv
bone
marrow
dc
seed
tissu
sampl
environ
attempt
detect
tissu
damag
pathogen
entri
inflamm
malignantli
transform
cell
take
particl
molecul
process
short
peptid
present
result
peptid
mhc
molecul
dc
use
differ
rout
captur
ag
includ
phagocytosi
micro
macropinocytosi
receptormedi
endocytosi
importantli
receptormedi
endocytosi
exploit
target
taa
dc
immatur
dc
peripher
tissu
character
high
ag
captur
activ
low
surfac
mhc
level
costimulatori
molecul
well
tendenc
induc
toler
selfantigen
upon
recognit
danger
signal
dc
undergo
matur
process
character
reduct
ag
captur
activ
increas
mhc
costimulatori
molecul
express
cell
surfac
matur
dc
migrat
adjac
lymph
node
present
antigen
peptid
tcell
ag
present
costimulatori
molecul
express
secret
appropri
set
cytokin
chemokin
dc
facilit
differenti
tcell
effector
thelper
tcytotox
cell
respect
dc
thu
simultan
activ
ctl
respons
directli
kill
pathogen
affect
cell
thelper
respons
recruit
enhanc
activ
immun
cell
right
context
uniqu
abil
dc
activ
variou
arm
immun
system
achiev
power
effici
immun
respons
make
promis
candid
immunotherapeut
manipul
pathway
present
nucleat
cell
use
present
endogen
antigen
deriv
nucleu
cytoplasm
mhc
class
antigen
present
therefor
report
intracellular
bacteri
viral
infect
well
malign
transform
present
cell
result
intracellular
product
degrad
cytoplasm
proteasom
transloc
endoplasm
reticulum
er
via
transport
associ
antigen
present
tap
load
newli
form
mhc
class
molecul
mhc
class
ipeptid
complex
export
along
constitut
secretori
pathway
cell
membran
present
tcell
interact
mhc
class
ipeptid
complex
dc
tcell
receptor
tcr
tcell
induc
differenti
tcell
cytotox
tcell
capabl
kill
infect
transform
cell
fig
pathway
restrict
apc
includ
macrophag
dc
b
lymphocyt
use
present
exogen
antigen
exogen
antigen
taken
cell
endocytosi
found
earli
endosom
mildli
acid
cell
compart
contain
small
amount
proteas
earli
endosom
develop
late
endosom
acid
present
higher
proteolyt
activ
process
captur
ag
short
peptid
suitabl
mhc
present
chain
mhc
class
ii
molecul
assembl
er
associ
invari
chain
ii
occupi
peptidebind
groov
complex
mhc
class
ii
molecul
transport
late
endosom
also
refer
mhc
class
ii
compart
follow
partial
digest
ii
cathepsin
final
bind
exogen
peptid
mhc
class
iipeptid
complex
transport
cell
membran
peptid
present
tcell
induct
thelper
respons
support
enhanc
activ
immun
cell
fig
gener
ctl
respons
viral
infect
transform
cell
possibl
mhc
class
pathway
describ
howev
kind
threat
address
immun
system
apc
mhc
class
ii
pathway
pathway
exclus
gener
thelper
respons
obviou
everi
viral
infect
malign
transform
involv
apc
mani
pathogen
impair
antigen
present
host
cell
altern
mechan
must
exist
would
enabl
apc
gener
cytotox
tcell
respons
variou
exogen
threat
encount
pathway
inde
exist
uniqu
properti
dc
addit
mhc
class
mhc
class
ii
antigen
present
pathway
dc
present
exogen
antigen
mhc
class
molecul
tcell
pathway
term
crosspresent
impli
involv
mechan
mhc
class
mhc
class
ii
pathway
although
first
describ
three
decad
ago
detail
pathway
remain
poorli
understood
two
main
theori
attempt
explain
mechan
lead
mhc
class
load
endocytos
exogen
antigen
cytosol
track
suggest
antigen
transloc
endosom
cytosol
enter
cytosol
process
pathway
endocyt
track
hand
suggest
mhc
molecul
recycl
cell
membran
endosom
load
antigen
peptid
process
endosom
proteas
mention
earlier
anticanc
immun
requir
gener
specif
antitumor
ctl
respons
turn
requir
proper
antigen
present
part
mani
techniqu
tumor
cell
use
avoid
weaken
immun
system
substanti
reduc
express
mhc
class
ipeptid
complex
cell
surfac
sinc
tumor
cell
thu
poor
agpres
cell
crosspresent
tumor
antigen
dc
essenti
gener
tumorspecif
ctl
respons
addit
given
uniqu
abil
dc
initi
orchestr
variou
arm
immun
system
includ
recruit
activ
macrophag
natur
killer
nk
cell
thelper
cell
bcell
strong
comprehens
anticanc
immun
respons
hope
achiev
induc
cell
present
appropri
tumor
antigen
dc
immun
requir
appropri
antigen
present
dc
proper
manner
right
immun
context
allow
ag
uptak
process
present
mhc
molecul
parallel
dc
matur
tcell
prime
first
method
develop
dc
immun
involv
use
whole
tumor
cell
wtc
tumor
cell
lysat
either
alon
mix
adjuv
genet
modifi
express
adjuv
major
advantag
method
ag
identif
requir
multipl
ag
deliv
simultan
nevertheless
wtc
vaccin
method
show
limit
effici
clinic
trial
probabl
due
insuffici
interact
tumor
antigen
dc
puls
dc
antigen
protein
peptid
correspond
anoth
approach
proteinpuls
dc
capabl
present
ag
mhc
class
mhc
class
ii
molecul
long
halflif
mhc
class
present
hla
restrict
ie
need
patient
select
requir
appropri
process
protein
dc
may
difficult
achiev
peptidepuls
dc
hand
requir
process
still
show
limit
mhc
class
ii
present
short
halflif
mhc
class
present
hla
restrict
specif
total
tumor
mrna
process
present
mhc
class
class
ii
molecul
howev
requir
mrna
extract
tumor
sampl
thu
patientspecif
late
deliveri
tumor
agencod
plasmid
dna
emerg
promis
method
dc
immun
dna
vaccin
dc
genet
modifi
express
taa
dna
vaccin
advantag
sever
reason
enabl
present
multipl
epitop
fulllength
taa
mhc
class
class
ii
molecul
sinc
process
occur
within
cell
hlarestrict
addit
effici
gene
transfer
allow
continu
suppli
peptid
modifi
dc
genet
modif
dc
achiev
either
ex
vivo
gene
deliveri
method
includ
use
gene
gun
electropor
ultrasound
microinject
vivo
approach
includ
nake
dna
deliveri
viral
synthet
vector
ex
vivo
deliveri
offer
mani
advantag
extract
cell
cultur
undergo
matur
control
condit
absenc
inhibitori
signal
provid
tumor
cell
matur
statu
determin
readministr
sinc
transfect
occur
cultur
high
specif
achiev
select
cell
transfect
nevertheless
ex
vivo
gene
deliveri
carri
substanti
limit
process
labori
costli
timeconsum
patient
must
undergo
cytopheresi
follow
cultur
matur
acquir
cell
step
must
perform
patient
separ
reproduc
low
differ
qualiti
control
method
use
thu
limit
number
patient
would
expect
benefit
approach
henc
ex
vivo
gene
deliveri
like
becom
wide
market
moreov
transfect
matur
dc
show
poor
distribut
inject
site
ex
vivo
matur
impair
dc
traffick
lymph
node
critic
requir
crossprim
contrast
vivo
gene
deliveri
may
expect
becom
shelf
therapi
singl
product
suitabl
patient
vivo
gene
deliveri
produc
larg
scale
lower
cost
simpl
uniform
manufactur
product
control
procedur
enabl
reproduc
control
product
qualiti
addit
dc
target
differ
site
natur
environ
therebi
impair
natur
cours
matur
activ
reason
vivo
gene
deliveri
consid
mani
best
strategi
ag
deliveri
dc
vivo
gene
carrier
must
meet
import
requir
first
abl
incorpor
plasmid
dna
cargo
core
nanoparticl
stabl
enough
carri
cargo
circul
protect
degrad
second
abl
select
target
desir
cell
type
properli
intern
third
must
facilit
escap
endosom
cytoplasm
traffick
nuclear
transport
dna
unpack
date
effici
gene
deliveri
system
viral
vector
use
small
amount
dna
viral
vector
induc
high
transfect
effici
stabl
longterm
gene
express
unfortun
viral
vector
possess
seriou
safeti
issu
includ
toxic
immunogen
oncogen
numer
clinic
trial
termin
restrict
gene
size
anoth
major
limit
viral
vector
synthet
vector
correspond
cation
lipid
cation
polym
respect
term
lipoplex
polyplex
electrostat
bind
neg
charg
dna
main
drawback
vector
low
transfect
effici
compar
viral
vector
yet
synthet
vector
simpl
safe
easi
manufactur
larg
scale
carri
plasmid
unrestrict
size
moreov
easili
modifi
possess
desir
properti
includ
target
serum
stabil
reactiv
extern
signal
abil
stimul
immun
respons
fact
cation
polym
may
provid
immun
stimul
mimic
nuclear
local
signal
nl
facilit
nuclear
transport
cargo
poli
llysin
pll
first
cation
polym
develop
gene
deliveri
pll
linear
polypeptid
present
llysin
residu
repeat
unit
fig
first
gener
cation
polym
bear
group
electrostat
bind
neg
charg
nucleic
acid
interact
neg
charg
cell
membran
larg
number
activ
function
amin
group
allow
easi
modif
target
ligand
howev
transfect
effici
pll
low
mediat
escap
endosom
compart
releas
cytosol
overcom
barrier
pll
usual
use
combin
chloroquin
although
use
agent
limit
due
cytotox
anoth
disadvantag
pll
polyplex
transfect
effici
significantli
influenc
serum
probabl
due
rapid
bind
negativelycharg
serum
compon
furthermor
vivo
applic
pll
polyplex
complic
high
level
cytotox
lack
vivo
stabil
low
transfect
effici
imidazol
group
pka
introduc
pll
improv
buffer
capac
therebi
enhanc
transfect
effici
pll
high
imidazol
content
mediat
high
gene
transfect
effici
gene
express
level
close
pei
discuss
exhibit
low
cytotox
pegyl
pll
also
improv
cytotox
profil
final
wherea
found
plldna
complex
taken
dc
plldna
alter
dc
phenotyp
surfac
marker
express
complex
plasmid
dna
encod
chicken
egg
ovalbumin
ova
pllcoat
polystyren
ps
particl
induc
high
level
tcell
well
ovaspecif
antibodi
mice
inhibit
tumor
growth
challeng
ova
express
tumor
cell
pllbase
microspher
display
mannan
mannosidemodifi
surfac
target
mannos
receptor
discuss
readili
phagocytos
dc
macrophag
howev
neither
surfaceassembl
mannan
mannosidemodifi
microspher
could
stimul
dc
matur
thu
despit
promis
result
shown
earli
studi
pll
like
find
clinic
applic
poli
ethylenimin
pei
second
gener
one
use
polyc
gene
deliveri
linear
pei
secondari
amino
group
almost
proton
physiolog
condit
branch
pei
present
primari
secondari
amin
also
tertiari
amin
twothird
amino
group
branch
pei
proton
physiolog
condit
transfect
effici
pei
depend
molecul
weight
pei
nitrogendna
phosphat
charg
ratio
np
cell
type
everi
third
posit
polym
backbon
occupi
proton
amino
group
fig
cation
charg
densiti
high
allow
condens
neg
charg
dna
physiolog
condit
pei
nitrogen
atom
proton
leav
facilit
import
step
endosom
escap
socal
proton
spong
effect
thu
pei
popular
effect
polymer
transfect
reagent
cite
date
howev
posit
charg
peidna
polyplex
caus
seriou
problem
includ
adsorpt
cell
neg
charg
blood
compon
recognit
immun
system
compon
result
rapid
clearanc
circul
cytotox
nontarget
cell
overcom
limit
pei
conjug
hydrophil
polym
ie
poli
ethylen
glycol
peg
hyaluron
acid
ha
differ
molecular
weight
peg
wildli
use
drug
gene
deliveri
system
shield
charg
immunogen
toxic
segment
result
less
toxic
stealth
particl
evad
immun
system
thu
avoid
rapid
clearanc
circul
conjug
peg
pei
previous
shown
increas
polyplex
solubl
serum
stabil
reduc
cytotox
shield
high
posit
charg
pei
pegyl
pei
howev
show
lower
transfect
effici
compar
peidna
complex
also
lack
cellspecif
ligat
peidna
complex
molecul
target
dc
uptak
receptor
significantli
increas
transfect
effici
approach
target
dc
receptor
gener
involv
either
natur
receptor
ligand
use
antibodi
rais
specif
receptor
target
dc
cell
surfac
receptor
may
also
provid
cell
activ
signal
differ
dc
receptor
use
facilit
target
deliveri
gene
drug
carrier
dc
includ
fc
receptor
studi
protein
purpos
member
ctype
lectin
receptor
clr
famili
clr
famili
receptor
share
structur
homolog
carbohydr
recognit
domain
crd
specif
sugar
residu
bound
calciumdepend
manner
one
clr
mannos
receptor
mr
wide
use
receptor
target
dc
use
mannos
mannan
sever
studi
demonstr
mannosylatedpei
conjug
effect
gene
deliveri
via
mr
transfect
potenti
primari
human
mous
dc
found
rather
low
might
due
low
affin
carbohydr
ligand
receptor
usual
low
millimolar
rang
thu
limit
vivo
transfect
effici
eight
adjac
crd
mr
may
help
increas
bind
affin
specif
polyplex
contain
mannosyl
glycan
multival
display
recent
describ
design
multival
mannosyl
peidna
complex
bear
mono
trival
mannos
ligand
target
mrposit
dc
complex
bear
mono
trival
mannos
manpegbpeidna
respect
safe
demonstr
significantli
higher
vitro
transfect
effici
dc
mannosyl
complex
inject
tail
base
mice
h
postinject
percentag
gfp
posit
cell
entir
cell
popul
cell
taken
inguin
lymph
node
measur
examin
entir
cell
popul
extract
lymph
node
peidna
complex
show
detect
gfp
activ
signific
chang
observ
treatment
fig
howev
significantli
effici
transfect
dc
collect
inguin
lymph
node
compar
polyplex
prepar
pegbpeidna
peidna
fig
one
challeng
target
mr
hold
true
abovement
receptor
exclus
express
dc
also
sever
cell
type
mr
exampl
also
express
monocyt
subset
endotheli
cell
tumorassoci
macrophag
furthermor
synthesi
carbohydr
ligand
analog
especi
multival
complex
carbohydr
often
requir
mani
timeconsum
low
yield
step
stereochemistri
carbohydr
ligand
difficult
control
product
difficult
purifi
frequent
use
altern
carbohydr
ligand
antibodi
rais
dc
receptor
ie
integrin
fc
receptor
dcsign
mr
even
human
may
still
elicit
advers
immun
respons
decreas
effici
treatment
induc
autoimmun
sideeffect
use
peptid
ligand
remain
nonetheless
promis
method
target
dc
receptor
ligand
easili
synthes
possess
immunogen
show
high
select
dc
tabl
accordingli
peptid
ligand
could
serv
dctarget
moieti
sought
fusion
peptid
bind
nucleic
acid
electrostat
interact
previous
exploit
specif
deliveri
sirna
dc
vitro
vivo
also
use
silenc
immunosuppress
molecul
dc
induc
strong
human
tcell
immun
respons
target
peptid
tabl
recent
studi
group
mediat
specif
deliveri
pegylatedpeidna
polyplex
dc
polyplex
show
signific
transfect
effici
dc
decor
peptid
endotheli
cell
transfect
effici
observ
higher
peidna
signifi
potenti
use
polyplex
immunotherapi
via
dc
polyamidoamin
pamam
dendrim
hyperbranch
symmetr
flexibl
monodispers
polymer
molecul
fig
szoka
et
al
firstli
investig
pamam
cascad
polym
nonvir
gene
deliveri
vector
polym
ammonia
initi
core
amidoamin
repeat
unit
differ
gener
stepwis
synthesi
result
product
uniform
term
structur
size
bear
welldefin
number
primari
tertiari
amin
surfac
primari
amin
proton
result
extrem
posit
charg
surfac
enabl
dna
bind
stabl
complex
interact
cell
membran
tertiari
amin
interior
polyplex
proton
endow
dendrim
ph
buffer
capac
enabl
endosom
escap
polyplex
follow
cellular
uptak
properti
addit
nonimmunogen
natur
make
pamam
dendrim
altern
highli
effici
highli
immunogen
viral
vector
howev
major
drawback
pamam
dendrim
low
gener
dendrim
lower
show
poor
transfect
effici
dendrim
high
gener
higher
effici
transfect
agent
yet
possess
seriou
cytotox
addit
synthesi
high
gener
dendrim
high
cost
laborconsum
process
last
sever
day
make
less
like
design
larg
scale
product
mannosyl
dendrim
conjug
ova
specif
target
dc
induc
crosspresent
vivo
moreov
preimmun
mannosyl
pamamova
lead
delay
onset
melanoma
develop
slower
kinet
tumor
growth
increas
surviv
ovaimmun
mice
dendrim
bear
dcsign
ligand
multival
present
also
achiev
effici
dc
target
properti
howev
affect
dc
matur
postul
mannosyl
dendrim
oppos
dcsignmodifi
dendrim
may
trigger
dcsign
also
mannosespecif
clr
contribut
dc
matur
activ
dendrim
conjug
mhc
class
iitarget
peptid
padr
tabl
surfaceload
dna
shown
effect
transfect
murin
human
apc
vitro
appli
subcutan
conjug
preferenti
transfect
dc
drain
lymph
node
promot
gener
high
affin
tcell
elicit
reject
establish
tumor
chitosan
linear
polysaccharid
fig
obtain
deacetyl
parent
polym
chitin
compound
wide
distribut
natur
chitosan
compos
randomli
distribut
link
dglucosamin
deacetyl
unit
nacetyldglucosamin
acetyl
unit
appar
pka
valu
chitosan
biodegrad
biocompat
polym
low
immunogen
antibacteri
activ
previous
shown
nontox
test
anim
human
due
properti
chitosan
attract
drug
gene
deliveri
high
densiti
posit
charg
along
polymer
chain
contribut
condens
neg
charg
dna
frequent
sirna
molecul
compact
structur
thu
protect
degrad
blood
nucleas
promot
cellular
uptak
chitosan
also
possess
adhes
properti
interact
glycoprotein
mucu
thu
use
mucoadhes
drug
deliveri
system
adsorpt
enhanc
dna
plasmid
incorpor
chitosan
nanoparticl
abl
induc
dc
matur
increas
secret
cell
pulmonari
mucos
immun
howev
unless
modifi
chitosan
low
solubl
physiolog
ph
significantli
limit
use
mani
applic
chemic
modif
chitosan
perform
improv
solubl
physiolog
ph
includ
pegyl
quatern
amin
group
chitosan
howev
transfect
effici
chitosanbas
deriv
report
far
gener
superior
pei
variou
dctarget
chitosanbas
dna
deliveri
formul
design
overcom
major
obstacl
face
clinic
develop
chitosan
name
lack
cellspecif
low
transfect
effici
mannosyl
chitosandna
complex
effici
transfect
dc
compar
watersolubl
chitosandna
induc
better
product
dc
mannosylatedchitosanentrap
peihbvdna
complex
induc
significantli
enhanc
serum
antibodi
product
ctl
level
intramuscular
immun
biotinyl
chitosan
nanoparticl
modifi
bifunct
fusion
protein
bffp
vector
achiev
dcselect
target
bffp
recombin
fusion
protein
consist
truncat
corestreptavidin
fuse
singl
chain
antibodi
scfv
intranas
administr
plasmid
dnaload
bffpchitosan
nanoparticl
along
dc
matur
stimuli
enhanc
amount
mucos
iga
well
system
igg
nucleocapsid
n
protein
sever
acut
respiratori
syndrom
coronaviru
sarscov
final
improv
low
transfect
effici
chitosanlinkedpeidna
complex
design
show
high
transfect
effici
low
cytotox
toward
dc
vaccin
dc
transfect
chitosanlinkedpeidna
encod
melanomaassoci
antigen
slightli
improv
resist
melanoma
challeng
poli
lactidecoglycolid
fig
fda
european
medicin
agencyapprov
polym
drug
deliveri
system
parenter
administr
biocompat
biodegrad
polym
slowli
degrad
vivo
hydrolysi
byproduct
lactic
glycol
acid
easili
metabol
excret
dc
macrophag
appear
high
affin
plga
particl
high
level
intern
antigenload
particl
demonstr
vitro
vivo
set
plga
microspher
carri
protein
antigen
antigenencod
plasmid
dna
capabl
elicit
potent
antigenspecif
immun
respons
plga
also
affect
express
matur
marker
cytokin
product
dc
capac
appear
driven
uniqu
physic
featur
plga
particl
ie
surfac
charg
shape
rate
polym
degrad
mechan
lead
matur
induct
dc
howev
remain
unclear
respect
stabil
plga
particl
antigenencod
plasmid
dna
offer
advantag
proteinbas
immunomodul
lose
biolog
activ
respons
small
chang
tertiari
quaternari
structur
formul
dna
deliveri
dc
improv
use
liganddecor
plga
particl
mannosegraft
plga
nanoparticl
lead
signific
enhanc
ova
accumul
inflam
colon
compar
healthi
one
underlin
benefit
activ
target
macrophag
dendrit
cell
diseas
tissu
mannandecor
ovaload
plga
nanoparticl
simultan
enhanc
antigenspecif
tcell
respons
vaccin
mice
modif
plga
microparticl
peptid
tabl
significantli
improv
dc
antigen
present
vitro
increas
rate
extent
microspher
transloc
dc
macrophag
vivo
plga
also
util
combin
cation
polym
gene
express
dc
without
target
ligand
plga
scaffold
encapsul
peidna
granulocytemacrophag
colonystimul
factor
gmcsf
led
signific
increas
gene
express
high
level
express
persist
period
time
yet
sinc
plga
nanoparticl
hydrophob
natur
tend
form
aggreg
reduc
effici
system
addit
plga
particl
opson
immun
system
compon
degrad
reach
destin
anoth
drawback
plga
deliveri
genet
vaccin
stem
sustain
releas
properti
plga
particl
releas
cargo
slowli
day
even
week
vivo
may
exocytos
cell
degrad
lysosom
much
shorter
period
time
suffici
amount
cargo
releas
moreov
dc
die
within
day
activ
migrat
drain
lymph
node
henc
even
fast
degrad
plga
system
fulli
releas
encapsul
dna
within
week
meet
rapid
releas
kinet
criteria
thu
fail
induc
high
level
target
gene
express
final
hydrolysi
plga
lead
low
ph
within
particl
thu
dna
degrad
reason
despit
promis
result
obtain
anim
model
clinic
trial
plga
limit
use
sens
deliveri
antigen
dc
carri
tremend
potenti
immun
modul
specif
cancer
immunotherapi
manipul
variou
polymer
nanomedicin
dna
deliveri
rang
linear
homopolym
block
copolym
branch
polym
well
combin
differ
type
polym
select
reduc
cytotox
facilit
endocytosi
particl
dc
routin
examin
abil
modul
dc
macrophag
ultim
dna
deliveri
system
also
induc
dc
matur
activ
would
advantag
main
challeng
success
vivo
gene
transfer
dc
cytotox
associ
mani
cation
polym
gene
carrier
lack
cell
specif
rel
low
transfect
effici
compar
viral
vector
togeth
fact
dc
compos
cell
peripher
tissu
gene
system
limit
success
unless
target
given
number
target
molecul
immunemodulatori
agent
chemokin
growth
factor
antigen
consid
dcspecif
deliveri
larg
number
potenti
use
formul
dc
manipul
avail
target
dc
vivo
tumor
antigenencod
plasmid
dna
elicit
effect
longlast
tumor
antigenspecif
immun
minim
inconveni
patient
furthermor
dna
deliveri
formul
stabl
extend
period
time
enhanc
antigen
present
mhci
mhcii
molecul
prefer
respect
clinic
translat
efficaci
nonvir
gene
deliveri
dc
depend
combin
intellig
materi
design
appropri
tumor
specif
antigenencod
dna
immunostimulatori
molecul
promot
dc
matur
activ
